Immediate Impact

1 from Science/Nature 59 standout
Sub-graph 1 of 24

Citing Papers

The sleep–circadian interface: A window into mental disorders
2024 Standout
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial
2023 Standout
3 intermediate papers

Works of Corinne Staner being referenced

Cognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms
2018
Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia
2017
and 2 more

Author Peers

Author Last Decade Papers Cites
Corinne Staner 293 295 186 12 490
Sylvie Chouinard 250 187 46 14 420
Stephan Krieger 203 136 82 11 570
Christine M. Walsh 273 141 110 19 506
David J. Kupfer 287 290 143 11 517
Nadine Petrovsky 213 119 45 19 521
H.A. Droogleever Fortuyn 296 266 136 9 511
Catherine Hatfield 149 138 158 9 435
E. DuBoff 168 354 53 12 554
Gabriel Esquivel 72 196 43 18 491
Bernd Strebel 87 79 123 11 441

All Works

Loading papers...

Rankless by CCL
2026